secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vera Therapeutics, Inc. (VERA)
CIK:        0001831828
Form:       8-K
Filed at:   2026-07-09T12:00:16+00:00
Accession:  0001193125-26-299165
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Vera Therapeutics announces CRO transition: Turner to Special Advisor, Bowman appointed Chief Regulatory Officer
--------------------------------------------------------------------------------

- William Turner steps down as Chief Regulatory Officer, becomes Special Advisor for Regulatory Affairs effective August 3, 2026.
- Nancy Bowman, M.D., Ph.D., appointed as new Chief Regulatory Officer, effective August 3, 2026.
- Transition appears planned; no reason for departure given.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831828/000119312526299165/0001193125-26-299165-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831828/000119312526299165/vera-20260709.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-299165

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer